Major depressive disorder (MDD) is a leading cause of disability worldwide and unfortunately no treatment without side effects is available. Previous reports have found unbalanced glutamate-glutamine cycle in the medial prefrontal cortex of mice with depression, which led to the interest in glutamine synthetase as a potential therapeutic target for treating MDD, since this enzyme is a regulator of this cycle.
An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used against cancer. Scientists at the University of Pittsburgh engineered this strain with a double break, which is effective and safer after an intravenous administration, according to their results in nonhuman primates and mice.
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different proteins.
Centre National de la Recherche Scientifique (CNRS) and Université Grenoble Alpes have developed new iridium complexes acting as photosensitizers for photodynamic therapy and reported to be potentially useful for the treatment of cancer.
Ono Pharmaceutical Co Ltd., Vanderbilt University and Wuxi Apptec Co. Ltd. have disclosed potassium channel subfamily K member 2 (TREK-1; KCNK2) and or member 10 (TREK-2; KCNK10) blockers reported to be useful for the treatment of depression, schizophrenia, anxiety disorders and bipolar disorder, among others.
An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent details new cannabinoid CB2 receptor modulators reported to be useful for the treatment of neuropathic pain, asthma, osteoporosis, inflammation, psychosis, cancer, malaria, gastrointestinal disorders, allergy and immunological disorders, among others.
Odyssey Therapeutics Inc. has reported new receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors described as potentially useful for the treatment of autoimmune diseases, chronic granulomatous disease, neurodegeneration, inflammatory disorders and cancer.
Prothena Biosciences Ltd. and Vanderbilt University have jointly discovered dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, diabetes, cardiovascular disorders and Down syndrome.
Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers retaining wild-type p53.
RSS
